Protagonist Therapeutics Inc. (PTGX) has grabbed fresh attention after being listed among billionaire Tom Steyer’s top stock picks, and investors are weighing a recent FDA approval, a juicy partnership with a major pharmaceutical company, and a steadily growing stake held by a prominent hedge fund. Farallon Capital has quietly built its position since 2017, and the company’s two lead programs—an oral peptide for plaque psoriasis and an injectable hepcidin mimetic for a rare blood disorder—are now driving both upside hopes and the usual biotech uncertainties. This piece lays out who owns what, what the drugs do, how the commercial plan works, and the key milestones that could move the stock moving forward.
Farallon Capital first showed up in PTGX’s 13F filings in late 2017 with roughly 900,000 shares, and over successive quarters the fund increased that exposure until filings for the fourth quarter of 2025 reported about 6.1 million shares. That kind of long-term accumulation signals conviction from a large, sophisticated investor and puts Protagonist on the radar of other institutional managers. The company itself is a U.S.-based discovery and development firm focused on peptide therapeutics that aim to replace or rival established biologic treatments.
The headline asset is Icotyde, described as a first-in-class investigational targeted oral peptide developed for adults and pediatric patients 12 years and older with moderate-to-severe plaque psoriasis, and it recently cleared FDA approval and moved into commercial launch. What sets Icotyde apart is that it’s a once-daily oral IL-23R peptide, combining the simplicity of a pill with efficacy levels investors hope will challenge injectable biologics. That oral convenience is the core narrative hedge funds and analysts are using when they talk about Icotyde’s disruptive potential in a market dominated by injections.
Protagonist didn’t go it alone on Icotyde: the molecule was advanced in collaboration with a large pharmaceutical partner that will handle global marketing and sales, enabling Protagonist to focus on discovery and collect royalties. The commercial setup translated into a $50 million milestone payment following approval, and the company remains eligible to receive up to $580 million more tied to future regulatory and sales targets. For investors, that structure offers the appeal of high-margin royalty revenue without the burden of building and funding a worldwide sales force, although it also concentrates commercial execution risk in the partner.
On the hematology side, Rusfertide represents another promising program: it is a first-in-class injectable mimetic of the natural hormone hepcidin in Phase 3 development for polycythemia vera, a rare blood disorder characterized by excessive red blood cell production. If Phase 3 results confirm safety and durable control of hematocrit levels, Rusfertide could address an unmet need and open a pathway to meaningful market opportunity in a focused specialty indication. That dual-program pipeline gives Protagonist diversified clinical shots on goal, which many investors find appealing compared with single-asset microcaps.
Investor reaction has been a blend of enthusiasm and caution: hedge funds and notable managers view the oral psoriasis drug as a material threat to injectable biologics because it promises both convenience and targeted action, yet biotech stocks remain volatile and subject to execution risk. Tom Steyer’s favorable placement of PTGX on his list amplified interest among retail and institutional buyers, but the stock’s trajectory will hinge on real-world uptake, payer coverage, and how effectively the marketing partner communicates benefits to physicians and patients. Milestone payments help the balance sheet now, but recurring revenue and durable commercial traction are what ultimately determine valuation.
Upcoming catalysts to monitor include commercial launch metrics for Icotyde, any reported sales-based milestone achievements, and Rusfertide Phase 3 readouts, all of which could materially impact sentiment and the company’s revenue profile in the months ahead. Investors should weigh the upside tied to first-in-class differentiation and strong institutional backing against the usual biotech hazards of regulatory, reimbursement, and partner-execution risk. Disclosure: None.
